# US 2019/0117572 A1 · Microfluidic-formulated leukosome compositions and fabrication methods therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0117572 A1
- Document ID: US20190117572A1
- Status: Published application
- Kind: A1
- Application number: 15/915,055
- Filed: 2018-03-07
- Published: 2019-04-25
- Earliest claimed: 2016-02-22
- Assignees: The Methodist Hospital
- Applicants: The Methodist Hospital
- Inventors: Ennio Tasciotti; Roberto Molinaro
- Web page: https://patentgrep.com/patent/US20190117572A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/1273: Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 47/6917: {the form being a lipoprotein vesicle, e.g. HDL or LDL proteins}
- A61K 49/0086: {Polymersome, i.e. liposome with polymerisable or polymerized bilayered-forming substances}
- A61K 49/1812: {liposomes, polymersomes, e.g. immunoliposomes}
- A61K 51/1237: {Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances}
- A61P 35/00: Antineoplastic agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods for designing and manufacturing biomimetic proteolipid nanovesicles using a microfluidic approach, and in particular, a NanoAssemblr®-based platform, which allows for the high-throughput, reproducible, and scalable production of nanoparticles, without affecting their pharmaceutical and biological properties. These nanovesicles, which are composed of synthetic phospholipids and cholesterol, enriched of leukocyte membranes, and surrounding an aqueous core, possess remarkable properties for targeting compounds of interest to particular mammalian cell and tissue types.

## Claims

### Claim 1

A method of preparing a population of biomimetic proteolipid nanovesicles composed of synthetic phospholipids and cholesterol, enriched of leukocyte membrane fragments, and surrounding an aqueous core, the method comprising:
a) dissolving predetermined amounts of two or more selected phosphocholine-based phospholipids, and cholesterol in ethanol to a final lipid concentration of approximately 9 mM to produce an organic lipid solution;
b) dissolving a predetermined amount of at least one selected membrane protein in water to produce an aqueous protein solution;
c) loading the organic lipid solution of (a) into the organic phase inlet of a microfluidic mixer, and loading the aqueous protein solution of (b) into the aqueous phase inlet of the microfluidic mixer, wherein the microfluidic mixer is set to a predetermined reaction temperature; and
d) adjusting the flow rates of each inlet stream and the flow ratio between each of the inlet streams of the microfluidic mixer to produce the population of biomimetic proteolipid nanovesicles therefrom.

### Claim 2 (depends on 1)

The method of claim 1, wherein adjustment of the flow rates or the flow ratio results in the production of a population of biomimetic proteolipid nanovesicles having a desired property selected from the group consisting of a consistent size, a consistent size homogeneity, a selected amount of protein incorporation into the membrane fragments, nanovesicle stability, and any combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, further comprising purifying the population of biomimetic proteolipid nanovesicles so produced by dialysis, ultracentrifugation, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the selected flow rate is 1 mL/min, the selected flow ratio is 2:1 (organic phase-to-aqueous phase), and the predetermined reaction temperature is approximately 45° C.

### Claim 5 (depends on 5)

The method of claim 5, wherein the efficiency of protein incorporation into the leukocyte membrane fragments is at least 40% to 60% higher than that of biosimilar nanovesicles prepared by conventional thin-layer evaporation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the total number of nanovesicles produced per gram of lipid is at least 100% higher than that of biosimilar nanovesicles prepared by conventional thin-layer evaporation.

### Claim 7 (depends on 6)

The method of claim 6, wherein the total number of nanovesicles produced per gram of lipid is at least 200% higher than that of biosimilar nanovesicles prepared by conventional thin-layer evaporation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the efficiency of protein incorporation into the membrane fragments is at least 10-fold higher than for biosimilar nanovesicles prepared by conventional thin-layer evaporation.

### Claim 9 (depends on 8)

The method of claim 8, wherein the efficiency of protein incorporation into the membrane fragments is at least 20-fold higher than for biosimilar nanovesicles prepared by conventional thin-layer evaporation.

### Claim 10 (depends on 1)

The method of claim 1, wherein the proteolipid nanovesicles are about 100 to about 1000 nm in average diameter.

### Claim 11 (depends on 1)

The method of claim 1, wherein the selected phosphocholine-based phospholipids are selected from the group consisting of phosphatidylcholine, egg phosphatidic acid, 1,2-dioleoyl-sn-glycerophosphocholine (DOPC), 1,2-dioleoyl-sn-glycerophosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycerophosphocholine (DPPC), 1,2-distearoyl-sn-glycerophosphocholine (DSPC), and any combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the resulting population of biomimetic proteolipid nanovesicles comprises substantially spherical, unilamellar vesicles.

### Claim 13 (depends on 1)

The method of claim 1, wherein the resulting population of biomimetic proteolipid nanovesicles are stable in solution at 4° C. for about two to about three weeks.

### Claim 14 (depends on 1)

The method of claim 1, wherein the resulting population of biomimetic proteolipid nanovesicles are stable in solution at 4° C. for at least 24 days after synthesis, without significant change in either average nanovesicle diameter or particle size homogeneity.

### Claim 15 (depends on 1)

The method of claim 1, wherein the proteolipid nanovesicles are from about 100 mm to about 1000 nm in average diameter.

### Claim 16 (depends on 15)

The method of claim 15, wherein the proteolipid nanovesicles are from about 200 mm to about 600 nm in average diameter.

### Claim 17 (depends on 1)

The method of claim 1, wherein the protein-to-lipid ratio is from about 1:50 (wt./wt.) to about 1:500 (wt./wt.).

### Claim 18 (depends on 17)

The method of claim 17, wherein the protein-to-lipid ratio is from about 1:100 (wt./wt.) to about 1:300 (wt./wt.).

### Claim 19 (depends on 1)

The method of claim 1, wherein the resulting population of biomimetic proteolipid nanovesicles further comprises a diagnostic or therapeutic agent, or a combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the therapeutic agent comprises an siRNA that is specific for a mammalian gene selected from the group consisting of BRAF, MEK, ERK1, and ERK2.

### Claim 21 (depends on 1)

A population of biomimetic proteolipid nanovesicles prepared by the method of claim 1.

### Claim 22 (depends on 21)

A drug delivery composition comprising the population of biomimetic proteolipid nanovesicles of claim 21.

### Claim 23 (depends on 22)

The drug delivery composition of claim 22, wherein the proteolipid nanovesicles comprise at least one self-tolerance protein or active fragment thereof on their surface selected from the group consisting of LFA-1, CD47, CD-45, CD-47, and MHC-1.

### Claim 24 (depends on 22)

The drug delivery composition of claim 22, further comprising at least one therapeutic agent, including, for example, a chemotherapeutic drug, an antibiotic, an analgesic, or a siRNA molecule.

### Claim 25 (depends on 22)

The drug delivery composition of claim 22, wherein the leukocyte membrane fragments are derived from human leukocyte plasma membranes.

### Claim 26 (depends on 22)

The drug delivery composition of claim 22, further comprising at least one therapeutic agent selected from the group consisting of an immune-stimulating agent, a tumor growth inhibitor, a protein, a peptide, an RNA molecule, a DNA molecule, an siRNA molecule, a RNAi molecule, a ssRNA molecule, a growth factor, an enzyme inhibitor, a binding protein, a blocking peptide, and any combination thereof.

### Claim 27 (depends on 22)

The drug delivery composition of claim 22, wherein the proteolipid nanovesicles are adapted configured to release the at least one therapeutic agent in response to an external stimulus, in response to a change in the environment of the population of biomimetic proteolipid nanovesicles, or as a result of degradation of the proteolipid nanovesicles.

### Claim 28 (depends on 22)

The drug delivery composition of claim 22, wherein degradation of the population of biomimetic proteolipid nanovesicles occurs via enzyme-facilitated biodegradation of one or more of the phospholipids or the cholesterol comprising them.

### Claim 29 (depends on 22)

The drug delivery composition of claim 22, wherein the leukosyte membrane fragments comprise at least one cellular-targeting moiety.

### Claim 30 (depends on 29)

The drug delivery composition of claim 29, wherein the at least one cellular-targeting moiety is selected from the group consisting of a chemically-targeting moiety, a physically-targeting moiety, a geometrically-targeting moiety, a ligand, a ligand-binding moiety, a receptor, a receptor-binding moiety, an antibody or an antigen-binding fragment thereof, and any combination thereof.

### Claim 31 (depends on 30)

The drug delivery composition of claim 30, wherein the at least a first cellular-targeting moiety comprises a plurality of distinct antigenic ligands that elicit one or more target-specific immune responses in a mammalian host cell that is contacted with the population of nanovesicles.

### Claim 32 (depends on 22)

The drug delivery composition of claim 22, further comprising a diagnostic agent.

### Claim 33 (depends on 32)

The drug delivery composition of claim 32, wherein the diagnostic reagent is selected from the group consisting of an imaging agent, a contrast agent, a fluorescent label, a radiolabel, a magnetic resonance imaging label, a spin label, and any combination thereof.

### Claim 34 (depends on 22)

The drug delivery composition of claim 22, comprising a chemically-targeting moiety that is disposed on the surface of the proteolipid nanovesicles, and that comprises a ligand, a dendrimer, an oligomer, an aptamer, a binding protein, an antibody, an antigen-binding fragment thereof, a biomolecule, or any combination thereof.

### Claim 35 (depends on 21)

A population of isolated mammalian cells comprising the population of biomimetic proteolipid nanovesicles of claim 21.

### Claim 36 (depends on 21)

A pharmaceutical formulation comprising the population of biomimetic proteolipid nanovesicles of claim 21, and a pharmaceutically-acceptable buffer, diluent, excipient, or vehicle.

### Claim 37 (depends on 36)

A kit comprising the pharmaceutical formulation of claim 36, and instructions for administering the composition to a mammal in need thereof, as part of a regimen for the prevention, diagnosis, treatment, or amelioration of one or more symptoms of a disease, a dysfunction, an abnormal condition, or a trauma in the mammal.

### Claim 38 (depends on 36)

A method for providing one or more active agents to a population of cells within the body of an animal, comprising administering to the animal an amount of the pharmaceutical formulation of claim 36, for a time effective to provide the one or more active agents to the population of cells within the body of the animal.

### Claim 39 (depends on 38)

The method of claim 38, wherein the animal is at risk for developing, is suspected of having, or is diagnosed with a tumor or a cancer.

### Claim 40 (depends on 36)

A method of targeting a diagnostic, therapeutic, or prophylactic agent to one or more inflamed sites within the body of a mammalian subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical formulation of claim 36.

### Claim 41 (depends on 40)

The method of claim 40, wherein the therapeutic agent comprises at least a first siRNA, DNA, ssRNA, RNAi, or any combination thereof.

### Claim 42 (depends on 40)

The method of claim 40, wherein the therapeutic agent further comprises at least a first chemotherapeutic agent.

### Claim 43 (depends on 40)

The method of claim 40, wherein accumulation of the biomimetic proteolipid nanovesicles is at least 8- to 13-fold higher in the inflamed site as compared to non-inflamed tissues when the formulation is administered systemically to the mammal.
